MCM
REGN icon

Murphy Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Murphy Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-650
Closed -$331K – 315
2015
Q2 		$331K Sell
650
-375
-37% -$183K 0.05% 246
2015
Q1 		$462K Sell
1,025
-275
-21% -$117K 0.07% 209
2014
Q4 		$533K Buy
+1,300
New +$511K 0.08% 199

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Murphy Capital Management's REGN Position: Q3 2015 in Review

Murphy Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 650 shares — an estimated $331K sold.

Murphy Capital Management first reported a position in REGN in Q4 2014 and held it in 3 quarters. The position peaked at $533K in Q4 2014. 563 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Murphy Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Murphy Capital Management sold 650 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $331K.
  • Murphy Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Murphy Capital Management's Regeneron Pharmaceuticals position peaked at $533K in Q4 2014.
  • 563 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Murphy Capital Management's 13F filing for Q3 2015, filed 14 Oct 2015.